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 Staphylococcus aureus is associated with several human diseases. Following 
the introduction of meticillin for the treatment of infections associated with 
penicillin-resistant Staphylococcus aureus, meticillin resistant S. aureus (MRSA) 
emerged. Recent reports indicate that some MRSA strains have acquired vanA 
gene encoding staphylococcal vancomycin resistance, thus constituting further 
pressures on clinical antibiotic use and infection control. To prevent the spread 
of such clones, rapid diagnostic assays are needed. We used all the vanA 
nucleotide sequences available at the National Centre for Biotechnology 
Information to perform multiple alignments in the clustalW suite at the European 
Bioinformatics Institute from which we designed and developed a new vanA PCR 
assay. The new vanA PCR assay generated 235bp amplicon through 40-cycles in 
55 min with negative predictive value of 100% and positive predictive value of 
100% and sensitivity of one colony-forming unit. Following primary isolation, the 
turn-around time was 2.5 h against ≥ 24 h by bacteriological methods. The new 
assay was validated on reference vancomycin-susceptible and vancomycin-
resistant staphylococcal strains (N=345) obtained from local, national and 
international standard supplies. PCR products were confirmed by nucleotide 
sequencing. Staphylococcal vancomycin resistance testing methods recently 
recommended by the CLSI were used to confirm staphylococcal vancomycin 
resistant phenotype. Use of multiple sequence data for oligo-design will help 
stay ahead of the bugs. The new vanA PCR assay can easily be integrated into 
the routine microbiology workflow especially for laboratories with slim budgets. 
Richer laboratories could easily convert the new vanA PCR assay from end-point 
platform to real-time PCR using fluorescent probes. 
©2013 BluePen Journals Ltd. All rights reserved 
 
 
INTRODUCTION 
 
Staphylococcus aureus has long been associated with 
diverse diseases of humans and other  animals  including  
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pneumonia, mastitis, gastroenteritis, bacteraemia, brain 
abscess and musculoskeletal disorders. S. aureus 
infections used to be treated successfully with penicillins, 
a large group of antibacterial agents which includes 
Penicillin G and meticillin. Before the emergence of 
meticillin-resistant S. aureus (MRSA), meticillin was 
found  to   be   active   against   strains  of   staphylococci  
 
 
 
 
 
resistant to penicillin G (Stewart et al., 1960). Following 
the broad-spectrum inactivation of penicillins and related 
antibiotics, including meticillin, by MRSA, the glyco-
peptide vancomycin was introduced in the USA in 1956 
(Schneierson et al., 1958) and is widely used against 
MRSA (Chambers, 1991; Stevens, 2006). 
The first clinical strain of MRSA with reduced 
vancomycin susceptibility, described as vancomycin-
intermediate S. aureus (VISA), was isolated from a 
surgical wound infection in Japan (Hiramatsu et al., 
1997a). Subsequently, dissemination in Japanese 
hospitals of strains of S. aureus heterogeneously 
resistant to vancomycin, including strains with 
vancomycin minimum inhibitory concentration (MIC) ≥ 8 
mg/L, was reported (Hanaki et al., 1998, Hiramatsu et al., 
1997b). In June 2002, vancomycin-resistant S. aureus 
(VRSA) with MIC ≥ 32 µg/mL was isolated from a swab 
obtained from a catheter exit site from a Michigan 
resident aged 40 years with diabetes, peripheral vascular 
disease and chronic renal failure (CDC, 2002). 
Subsequently, several other VRSA have been reported 
including the VRSA isolated from a patient in 
Pennsylvania (Tenover et al., 2004). Aside from the 
VRSA isolated within the USA between 2002 and 2006 
(Sievert et al., 2008), there are reports of VRSA from 
several parts of the world including Brazil (Lutz et al., 
2003), India (Tiwari and Sen, 2006), Italy (Chesi et al., 
2006) and Japan (Haraga et al., 2002).  
The Centre for Disease Control (CDC) team on the 
Michigan diabetic reported that the DNA sequence of the 
vanA gene from the VRSA isolate was identical to the 
vanA sequence of transposon Tn1546 and to the vanA 
sequence from the patient's Enterococcus faecalis isolate 
(Chang et al., 2003). Evolutionary genomics have shown 
that reservoir of MRSA and vancomycin-resistant 
Enterococcus, especially in wounds, chronic, 
rehabilitation and intensive care patients have been 
associated with the genomic escalation from MRSA to 
VRSA (Kobayashi et al., 2012; Zhu et al., 2010; Flannery 
et al., 2011; Rabinowitz et al., 2012; Thati et al., 2011). 
During co-habitation in such environments, MRSA 
acquire the vanA gene from Enterococcus species 
(Freitas et al., 2013; Gardete et al., 2012). Isolation of E. 
faecalis and E. faecium from human clinical specimens 
containing plasmids harbouring the entire vancomycin 
resistance gene cluster has been documented (Sharifi et 
al., 2012); while a recent report from North-eastern Iran 
described the phenotypic and genetic characterization of 
VRSA and E. faecalis ATCC 52199 from a patient which 
they demonstrated by sequencing and detection of a 
713bp PCR product from the vanA gene (Azimian et al., 
2012). 
Given that vancomycin had been the mainstay of 
MRSA treatment in some parts of the world (Gemmell, 
2004; Stevens, 2006), the emergence of vancomycin 
resistance in MRSA had posed a  new  level  of  threat  to  
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diagnostic microbiology, hospital infection control and 
antimicrobial chemotherapy (Hiramatsu, 1998; Linden, 
2008). Recent expert reviews have highlighted the need 
for more reliable and rapid genetic testing methods 
(Linden, 2008; Howden et al., 2010). In response to the 
highlighted need, we used multiple alignments to identify 
highly conserved motifs (HCMs) within the vanA gene 
sequences available at the National Centre for 
Biotechnology Information (NCBI). The HCMs were used 
to design and develop a set of PCR primers for the 
detection of 235bp amplicon from the vanA gene. The 
new vanA PCR assay was validated by sequencing of 
PCR amplification products and by conventional 
phenotypic techniques.  
 
 
MATERIALS AND METHODS 
 
Bacterial isolates, culture media and culture 
conditions 
 
All bacterial isolates used in this study (N=345) were sub-
cultured from the strain collections used for DNA 
microarray work in our laboratory (Spence et al., 2008). 
They include 53 reference strains obtained from the 
Network for Antibiotic Resistance in S. aureus (NARSA), 
the National Collection of Type Cultures (NCTC) and the 
National Centre for Industrial and Marine Bacteria 
(NCIMB). The others (n=292) were sub-cultured 
Nottingham local clinical staphylococcal strains. 
Staphylococcal strains obtained from the NARSA were 
isolated in the Biosafety Level 3 (BSL3) suite provided for 
work with such potentially hazardous (multi-drug resistant 
and hyper-virulent) bugs. A fine touch of the frozen stock 
(-80°C) was inoculated into brain heart infusion (BHI) 
broth (Oxoid, UK). Broth cultures were shaker incubated 
overnight (approximately 14-24 h) at 37°C, Gram stained 
and sub-cultured unto BHI plates incubated (37°C, 
overnight) for discrete colonies.  
 
 
Preparation of Inoculum turbidity standard 
 
The British Society for Antimicrobial Chemotherapy 
(BSAC) standardized disk susceptibility testing method 
version 6 (Andrews and BSAC, 2007) and the Clinical 
and Laboratory Standards Institute (CLSI) guidelines 
(CLSI, 2012) were used to prepare BaSO4 turbidity 
standard (0.5 McFarland standard). Briefly, 0.5 mL of 
solution A (0.048 M BaCl2 [1.17% w/v BaCl2. 2H2O]) was 
added to 99.5 mL of solution B (0.18 M H2SO4 [1% v/v]) 
with constant stirring. Using matched cuvettes with a 1.0 
cm light path, the OD(625nm) was measured on the 
spectrophotometer (BioMate3: ThermoSpectronic, NY, 
USA), blanking with water. The 0.5 McFarland standard 
was distributed into disposable screw-capped  bijou  tube  
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(Sterilin, UK) of the same size and volume as those to be 
used for matching the direct colony suspensions. The 
tubes were labelled with the date of preparation and the 
expiry date which is six months from the date of 
preparation, sealed tightly to prevent loss by evaporation 
and stored at room temperature protected from light. 
Before use, the inoculum standard was vigorously 
agitated on a vortex mixer and the absorbance was read 
to ensure stability.  
 
 
Preparation of standardized bacterial inoculum 
 
Using the 0.5 McFarland standard as a guide, a 
standardized bacterial inoculum was prepared by the 
direct colony suspension method (Collee et al., 1996) as 
approved by the BSAC and CLSI. From BHI plate, 4 
discrete colonies were re-suspended in sterile distilled 
water to equivalence of 0.5 McFarland standard and 
maintained briefly on a shaker incubator at 35°C to 
homogenize. The bacterial density which gave an 
OD(625nm) equivalent to that of 0.5 McFarland standard is 
referred to as the standardised inoculum. The 
standardised inoculum was used within 15 min for 
diverse applications including antibiotic susceptibility 
testing (AST) and for PCR. 
 
 
Design of PCR primers 
 
The primer design strategy is detailed in an unpublished 
doctoral thesis (Okolie, 2009). Briefly, all published vanA 
nucleotide sequences were sourced from the NCBI and 
used for multiple alignments in the clustalW suite 
(www.ebi.ac.uk/tools/clustalW). Common subsequences 
were located manually as described elsewhere (Mount, 
2004). Following identity search by BLAST 
(www.ncbi.nlm.nih.gov/BLAST/), the primers were 
purchased from Sigma (Sigma Genosys, Cambridge, UK) 
whose DNA calculator (www.sigma-
genosys.com/calc/DNACalc.asp) was used to weight the 
oligo sequences.  
 
 
Detection of bacterial DNA using the new vanA PCR 
assay  
 
Extraction of bacterial DNA was performed by a simple 
heat method (Okolie, 2009). Briefly, standardized 
bacterial suspension (0.5 mL) was heated for 10 min at 
98°C. Following centrifugation (13000 g, 20 s), the 
supernatant was used as template DNA for PCR 
amplification on an Eppendorfmastercycler (Eppendorf, 
Hamburg, Germany). The cycling conditions were 
described elsewhere (Nakagawa et al., 2005) with some 
modifications. Briefly, an initial single  cycle  for  4  min  at  
 
 
 
 
94°C was followed by 40 cycles consisting of 15 s at 
94°C and 10 s at 60°C with a final polymerisation at 72°C 
for 1 min and cooling at 8°C before gel electrophoresis. 
PCR optimization was performed as described elsewhere 
(McPherson and Moller, 2006; Sahdev et al., 2007). PCR 
products were resolved by horizontal submarine 
electrophoresis (Bio-Rad, USA) at 200 V for 30 min in 
Agarose gel (2%) containing ethidium bromide (0.5 
μg/mL), visualized using UV-transilluminator (UVP, 
Cambridge, UK) and the gel images were captured with 
the associated VisionWorks
TM
software.  
 
 
Nucleotide sequencing and genotypic identity of PCR 
products  
 
PCR products were purified from Agarose gels using 
GenElute™ according to the manufacturer (Sigma, UK). 
Sequencing reactions were prepared following the 
Applied BiosystemsBigDye
TM
protocol. Sequencing was 
performed on a Prism 310 Genetic analyser (Abbott 
Laboratories, USA). Identity of the sequence data 
obtained was analysed by BLAST.  
 
 
Phenotypic bacteriological tests used to support 
gene detection assays  
 
Except otherwise indicated, all media and reagents used 
for bacteriological work were supplied by the UK 
dehydrated bacteriological media supplier (Oxoid, 
Basingstoke, UK). Following growth on BHI plates to 
obtain discrete colonies, 10 mL of BHI broth was 
inoculated with four discrete colonies homogenously 
emulsified in the broth. The broth was incubated to a 
heavy growth (8 h) for Gram stain (identification). A 
standardized 0.5 MacFarland inoculum was made by 
diluting the heavily grown suspension and used for 
inoculation of a tube coagulase test and for antibiotic 
susceptibility tests by vancomycin agar screen (VAS) and 
disk diffusion (DD). 
Visual analogue scale (VAS) test was performed 
according to CLSI recommendations (CLSI, 2012). 
Briefly, autoclaved BHI agar was allowed to cool down to 
50°C in the water bath. Vancomycin supplement from 
Oxoid was incorporated to a concentration of 6.0 μg/mL. 
Four plates were inoculated per test sample to provide 
duplicate plates for the two temperature zones (30 and 
35°C). To obtain an inoculum with 10
4 
CFU, the 
standardized inoculum (10 μL) was diluted into 900μL of 
sterile normal saline. VAS plates were then inoculated 
with a 10 μL drop of the diluted inoculum by using a 
micropipette to deliver onto the agar surface, spotting an 
area of 10 to 15 mm at the centre of the VAS test plate. 
All plates were incubated for 24 h. As soon as they were 
inoculated, one set of duplicate plates were  incubated  at  
 
 
 
 
 
30°C, while the second set of duplicate plates were 
incubated at 35°C. VAS test plates were examined 
carefully for evidence of small colonies (>1 colony) or a 
film of growth, suggesting reduced susceptibility to 
vancomycin.  
Disk diffusion (DD) tests of oxacillin (1 μg), cefoxitin 
(30μg) and vancomycin (5 μg) were performed using the 
disk diffusion method of Kirby-Bauer according to the 
version 4 of the BSAC standardized disc susceptibility 
testing (Andrews and BSAC, 2007). Briefly, Mueller-
Hinton agar plates were overlaid with the standardized 
inoculum of the test strain and incubated (24 h, 35°C). 
The inhibition zone diameters were measured and 
interpreted accordingly.  
 
 
Determination of the sensitivity of the novel vanA 
PCR by limiting dilution method  
 
The sensitivity (also called the limit of detection, LoD) 
was determined by limiting dilution experiments (dilution-
to-extinction) as described in detail elsewhere (Okolie, 
2009). Briefly, ten-fold serial dilutions were performed on 
the standardized inoculum and were used to inoculate 
BHI plates. For each dilution tested, 10 μL volume of 
bacterial inoculum was inoculated onto quadruplicate BHI 
plates. Colonies were counted after 24 h of incubation at 
37°C and the mean of the quadruplicate was recorded. 
PCR tubes were inoculated with the same 10 µL volumes 
used to inoculate the plates. The lowest bacterial 
concentration whose PCR product gave a clear band on 
the Agarose gel was recorded as the sensitivity or LoD of 
the PCR assay.  
 
 
Validation of the novel vanA PCR assay on 
previously characterized strains  
 
The reliability of the new vanA PCR assay to detect the 
appropriate DNA sequence was tested by using 
previously characterized staphylococcal strains, 345 in 
number, as sources of DNA template. Reference 
staphylococcal isolates (n=53), including the 3 VRSA 
strains from NARSA, were first used to validate the novel 
vanA PCR assay. Further validation was performed on 
randomly selected Nottingham local clinical isolates 
(n=292) collected in the Nottingham area during the 
period from August 2003 to December 2004 and stored 
the laboratory (Spence et al., 2008). Validation of the new 
vanA PCR assay was conducted blindly. Without 
disclosing their genotypic and phenotypic properties, the 
new vanA PCR was used to test frozen stocks numerically 
identified as RSS001, RSS002, RSS007, etc. After testing, 
the results were compared against the Queen’s Medical 
Centre (QMC) previous characterization data. 
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RESULTS AND DISCUSSION 
 
Bioinformatics workup and oligo-design selects a 
235bp set of vanA primers 
 
Bioinformatics analysis resulted to the selection of primers 
for the amplification of a 235bp region from the vanA 
gene; forward sequence (vanA-F: 
AAGACTGCACGTTCAGGCTC) and the reverse 
sequence (vanA-R: GCTCGACTTCCTGATGAATACG). 
The 235bp marker selected for detection of the vanA 
gene following multiple alignments yielded very good 
results: No loss of amplification product and spurious 
amplification products. By using all of the vanA nucleotide 
sequences available at the NCBI at the time of design, 
we have offered the primers the highest chance of 
continuously being useful. The supplier’s DNA calculator 
is user friendly and we believe it is highly valuable for 
successful oligo-design.  
 
 
New vanA PCR assay validated by information on 
reference strains 
 
The three VRSA strains previously characterized by 
NARSA, namely VRS1, VRS2 and VRS3, all tested 
vanA-positive by the new vanA PCR assay (Figure 1). 
Expectedly, the VRSA strains were all resistant to 
vancomycin by both the VAS and the DD methods. The 
genetic and phenotypic information available on the 
reference strains uphold the validity of the new vanA 
PCR in its capacity to detect the S. aureus vanA gene 
reliably (Table 1). Thus the vanA PCR has a positive 
predictive value of 100% (100% PPV). The remaining 50 
reference staphylococcal strains from NARSA, NCTC 
and NCIMB were vanA-negative by the new PCR assay 
and susceptible to vancomycin by VAS and DD, which 
was 100% negative predictive value (100% NPV). The 
new vanA PCR assay did not generate false positive nor 
false negative results. Also, we did not encounter invalid 
(indeterminate) results. Invalid test results are a major 
cause of high turnover of approvals and withdrawals of 
molecular diagnostics (MDx) assays by Food and Drug 
Administration.  
 
 
Success of the oligo-design strategy for the new 
vanA PCR assay supports the recent move towards 
metagenomics 
 
One of the major challenges against the application of 
MDx to MRSA was that most of the assays were 
designed on one genome sequence. Single genome 
designs are ideal for gene cloning whereby only one 
genome needs be cloned from. In the case of MDx the 
outcomes   of   single  -  genome   oligonucleotides   were
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vanA, 235bp 
 
Figure 1. Specific amplification of 235bp from the vanA gene of VRSA. 100bp DNA 
Marker (Lane L), MSSA strain Sanger 476 (Lane 1), VRSA strain VRS 1 (Lane 2), VRSA 
strain VRS 2 (Lane 3), VRSA strain VRS 3 (Lane 4). 
 
 
 
Table 1. Reference staphylococcal strains (n=53) from standard supplies and the results obtained on testing them using the 
new vanA PCR assay. 
 
S/N Isolate identity
a
 
Nomenclature 
(species level)
b
 
Source 
Information at Source
c
 Experimental results
d
 
Phenotype vanA gene Phenotype vanA gene 
1 NRS1 S. aureus NARSA S _ S _ 
2 NRS102 S. aureus NARSA S _ S _ 
3 NRS103 S. aureus NARSA S _ S _ 
4 NRS110 S. aureus NARSA S _ S _ 
5 NRS111 S. aureus NARSA S _ S _ 
6 NRS112 S. aureus NARSA S _ S _ 
7 NRS113 S. aureus NARSA S _ S _ 
8 NRS114 S. aureus NARSA S _ S _ 
9 NRS123 S. aureus NARSA S _ S _ 
10 NRS13 S. aureus NARSA S _ S _ 
11 NRS147 S. aureus NARSA S _ S _ 
12 NRS149 S. aureus NARSA S _ S _ 
13 NRS153 S. aureus NARSA S _ S _ 
14 NRS157 S. aureus NARSA S _ S _ 
15 NRS158 S. aureus NARSA S _ S _ 
16 NRS162 S. aureus NARSA S _ S _ 
17 NRS164 S. aureus NARSA S _ S _ 
18 NRS165 S. aureus NARSA S _ S _ 
19 NRS167 S. aureus NARSA S _ S _ 
20 NRS170 S. aureus NARSA S _ S _ 
21 NRS171 S. aureus NARSA S _ S _ 
22 NRS172 S. aureus NARSA S _ S _ 
23 NRS176 S. aureus NARSA S _ S _ 
24 NRS179 S. aureus NARSA S _ S _ 
25 NRS182 S. aureus NARSA S _ S _ 
26 NRS185 S. aureus NARSA S _ S _ 
27 NRS188 S. aureus NARSA S _ S _ 
28 NRS191 S. aureus NARSA S _ S _ 
29 NRS192 S. aureus NARSA S _ S _ 
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Table 1.Continued. 
 
S/N Isolate Identity
a
 
Nomenclature 
(species level)
b
 
Source 
Information at Source
c
 Our experimental results
d
 
Phenotype vanA gene Phenotype vanA gene 
30 NRS194 S. aureus NARSA S _ S _ 
31 NRS227 S. aureus NARSA S _ S _ 
32 NRS229 S. aureus NARSA S _ S _ 
33 NRS231 S. aureus NARSA S _ S _ 
34 NRS233 S. aureus NARSA S _ S _ 
35 NRS244 S. aureus NARSA S _ S _ 
36 NRS248 S. aureus NARSA S _ S _ 
37 NRS249 S. aureus NARSA S _ S _ 
38 NRS255 S. aureus NARSA S _ S _ 
39 NRS260 S. aureus NARSA S _ S _ 
40 NRS265 S. aureus NARSA S _ S _ 
41 NRS70 S. aureus NARSA S _ S _ 
42 NRS71 S. aureus NARSA S _ S _ 
43 NRS72 S. aureus NARSA S _ S _ 
44 NRS8 S. epidermidis NARSA S _ S _ 
45 NRS9 S. haemolyticus NARSA S _ S _ 
46 NRS69 S. haemolyticus NARSA S _ S _ 
47 VRS1 S. aureus NARSA R + R + 
48 VRS2 S. aureus NARSA R + R + 
49 VRS3 S. aureus NARSA R + R + 
50 NCTC12217 S. lugdunensis NCTC NA NA S _ 
51 NCTC11042 S. haemolyticus NCTC NA NA S _ 
52 NCIMB9993 S. epidermidis NCIMB NA NA S _ 
53 NCIMB700787 S. capitis NCIMB NA NA S _ 
 
a
,Identity of isolate by type culture supplier; 
b
, species were identified to species level by supplier; 
c
, NA=information not available at 
source; 
d
, phenotype and gene detection results obtained in this study. 
 
 
 
unfortunately very poor. Like meticillin in the history of 
penicillins, most of those single-genome-inspired designs 
were finished and being useful long before they arrived at 
the market. MDx assay designers need to take into 
consideration that a diagnostic assay designed on a 
given genome in one part of the world will surely need to 
be applied to detect sequence(s) from other genomes 
elsewhere. Obviously, the cost of testing large numbers 
of isolates is huge, but the end user wants to see an 
assay that generates the appropriate amplification 
products or signals. One cannot predict what genomes 
would be tested in far distant places. Therefore, the MDx 
assay designer would be better off using as many 
genomes as possible from as far and near as possible. 
One key contribution the metagenomics projects are 
likely to achieve would be that of making metagenomic 
data available for design and development of MDx 
assays. Use of multiple alignments from metagenomic 
data will empower more reliable sequence detection even 
in the face of emerging genomes. This is one of the ways 
to stay ahead of genome evolution. More accurate 
diagnostics will in turn inform more effective treatments.  
New vanAPCR assay runs on optimized PCR factors 
 
The optimal factors upon which the new vanA PCR runs 
currently  are  summarized  (Table  2).  The  outcome   of  
every diagnostic assay revolves around the optimization 
of the assay factors. Primers, dNTPs, DNA template 
concentration, thermo-polymerase buffer and Taq DNA 
polymerase were optimised to determine the optimal 
concentrations which generated a clearly detectable 
amplification product in the new vanA PCR assay. 
Optimization of PCR was a major area of research during 
the early days of PCR. Following its advent, the PCR 
process had seen several modifications and applications 
even in terms of the cyclers and associated materials and 
methodologies, including the optimization of PCR 
experiments.  
As the PCR process extended from Cetus and Roche 
to several other research and development firms, a lot of 
improvement and optimization have been enabled. For 
example, the protocol for oil-overlay thermo-cyclers has 
been (or almost) overtaken by the heated-lid models 
which we used for this assay. Early  researchers  of  PCR
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Table 2. Summary of optimised PCR factors for the new vanA PCR assay. 
 
Factor Optimal value or concentration 
Primers  0.75 uM 
DNTPs  0.500 mM 
Taq DNA polymerase 10.0 U(NEB) 
Thermopolbuffer
a
 (pH 8.8 at 25°C) 
5 µL amounting to 20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 
0.1 % Triton X-100 
Time to complete a 50-cycle PCR run 90 min 
Cold or Hot-start PCR Hot-start applied  
 
a
, Experimental laboratory maintains controlled temperature, usually ~25ºC. 
 
 
 
optimization highlighted the influence on the fidelity of 
PCR by PCR factors including dNTP concentration, 
denaturation time and temperature, stringent annealing 
temperatures and magnesium chloride concentration 
(Tindall and Kunkel, 1988; Harris and Jones, 1997). It is 
no longer necessary to measure each component of the 
PCR thermopol buffer (Mg
++
, Cl
-
, SO4
--
, Tris, etc) as they 
now come (already made) alongside DNA polymerases. 
Roche even makes it easier by supplying MgCl2 along 
with Taq DNA polymerase and MgSO4 with Pwo DNA 
polymerase.  
Even the temperature regime has recently changed. 
Whereas, early PCR users were conversant with the 
three temperature-dependent steps of DNA denaturation, 
primer-template annealing and DNA synthesis by a 
thermostable DNA polymerase (Rychlik et al., 1990), 
while the new vanA PCR assay runs on the two 
temperature-driven steps recently reported for real-time 
PCR systems (Deurenberg et al., 2004; Nakagawa et al., 
2005). Several diverse applications of PCR had been 
developed across all disciplines of life sciences research, 
and no single protocol had proven appropriate for all 
situations (Harris and Jones, 1997), hence the list of 
factors influencing PCR would never be complete 
(Markoulatos et al., 2002).  
 
 
Speed of the new vanA PCR assay 
 
Following optimization, the new vanA PCR completes 
cycling in 55 min. The total time from sample preparation 
to gel documentation, also called the turn-around time 
(TAT), was 2.5 h. This is very reasonable compared with 
≥ 24 h required to identify staphylococcal vancomycin 
resistance following the isolation of Gram-positive cocci 
(GPC) in clusters. Though there is yet no commercial 
PCR-based assay for the detection of vanA gene in S. 
aureus, TAT of 2.5 h compares favourably with many 
commercial assays for mecA gene which encodes 
staphylococcal methicillin resistance. Diagnostic speed is 
especially important in blood cultures where the finding of 
GPC in clusters from positive blood cultures has  become 
a source for concern to infection control epidemiologists 
as well as for clinical anti-staphylococcal therapy teams. 
We hope this speed will be of help for all the teams 
concerned.  
Sensitivity of the new vanA PCR assay 
 
The sensitivity (or LoD) of the new vanA PCR assay was 
found to be 1 CFU by limiting dilution. So long as the 
template DNA was applied into the PCR, even if it was 
only one CFU, it was amplified. Scientific literatures show 
a wide variation in the LoD of PCR assays. It is not 
uncommon to find more sensitive PCR assays than the 
new vanA PCR, especially with real-time PCR assays, in 
which some of which have LoD of less than 1 CFU 
(Nakagawa et al., 2005). Some other PCR assays are 
less sensitive having LoD values of ≥10 CFU (Becker et 
al., 1998). Sensitivity remains one of the virtues of PCR 
as it is able to detect very small amounts of input DNA.  
 
 
Three phenotypic patterns of staphylococcal 
resistance to vancomycin observed 
 
Following the performance and interpretation of the AST 
according to CLSI and BSAC guidelines for vancomycin 
by DD method, three phenotypic patterns emerged. The 
typical vancomycin susceptible meticillin susceptible 
(VSMS) phenotype is marked by clear zone of inhibition 
surrounding the three disks (vancomycin, oxacillin and 
cefoxitin) used in this study. As exemplified by S. aureus 
strain Sanger 476, all VSMS yielded no PCR 
amplification product when tested with the new vanA 
PCR assay (Figure 1 Lane 2). MSSAs generally fall into 
this group.  
Another group of vancomycin susceptible staphylococci 
which also yielded no amplification product by the new 
vanA PCR is the vancomycin susceptible meticillin 
resistant (VSMR) phenotype. This group has most MRSA 
currently circulating in the world, and have been 
menacing anti-staphylococcal therapy since the advent of 
meticillin. S. aureus strains which are VSMR constitute 
the immediate predecessors  of  VRSAs  (Gardete  et  al.,  
 
 
 
 
 
2012).  
The three VRSA strains from NARSA belong to a third 
group. They harbour the vanA gene and are 
phenotypically vancomycin resistant thus completely 
different from the two vancomycin susceptible groups. 
They uniformly tested positive for vanA by the new PCR 
assay (Figure 1, Lanes 2, 3 and 4) and showed the 
vancomycin resistant meticillin resistant (VRMR) 
phenotype. This group constitute a heightened threat to 
anti-staphylococcal therapy. Recent reviews highlighted 
the identification of the genetic capacity for vancomycin 
resistance in the staphylococci as a current need 
(Winstanley and Courvalin, 2011), in response to which 
we developed this assay.  
Following on the identification of the need for rapid 
detection of the genetic capacity for vancomycin 
resistance, several laboratories have proffered DNA-
based diagnostic solutions to the emerging menace of 
VRSA. In India, there were staphylococcal isolates from 
which the mecA gene was detected by PCR and which 
expressed vancomycin resistance phenotypically, but 
detection of vanA and vanB genes by PCR was not 
possible (Tiwari and Sen, 2006). However, another 
research group from India reported what they believed 
was the first S. aureus isolates from India having both 
phenotypic and genetic confirmation of vancomycin-
resistance by PCR amplification of a vanHAXanalogue 
(Saha et al., 2008).  
In the expression of vancomycin resistance phenotype 
among Gram-positive bacteria, there are reports of 
detection of vanAB from enterococci (Sloan et al., 2004). 
However, the VRSA Investigative Team at CDC reported 
that PCR assays for vancomycin-resistant loci revealed 
only vanA (Chang et al., 2003; Sievert et al., 2008), thus 
upholding the centrality of the vanA gene, rather than the 
entire vancomycin resistance genetic island, in the 
mechanism of staphylococcal vancomycin resistance.  
 
 
VRSA was not found in Nottingham local clinical 
isolates of August 2003-December 2004  
 
VAS and DD phenotypic tests showed no expression of 
the vancomycin resistance phenotype among the 
Nottingham local strains and the 235bp marker for vanA 
gene was not detected, thus conferring a 100% negative 
predictive value (100% NPV) on the new vanA PCR 
assay. These findings strongly support the previous 
characterization data by QMC microbiology laboratory. 
These findings are also in agreement with the national 
staphylococcal vancomycin resistance data which 
showed that vancomycin resistance was not a problem in 
the UK at the time (Gemmell, 2004). The concordance 
between gene detection and phenotypic test results 
further establish the capacity of the novel vanA PCR 
assay to reliably confirm or rule out  the  genetic  capacity  
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for vancomycin resistance in a population of 
staphylococci. Our finding of concordance between PCR 
detection of vanA gene and phenotypic demonstration of 
staphylococcal vancomycin resistance is particularly 
important as recent publications have highlighted on the 
significance of finding Gram-positive cocci in clusters in 
blood cultures (Sogaard et al., 2007).  
 
 
Overall performance, applicability and limitations of 
the new vanA PCR assay  
 
The gene detection results obtained from applying the 
new vanA PCR assay corroborate the phenotypic data for 
the vancomycin susceptible and for the vancomycin 
resistant strains with 100% PPV and 100% NPV. The 
vanA primer pair detected the presence of the vanA gene 
from the genomic DNA of all the 3 (100%) S. aureus 
strains previously characterized as VRSA by NARSA. 
Such agreement between gene detection using the new 
vanA PCR assay and the phenotypic tests establishes 
the reliability of the new vanA PCR assay to identify 
vanA-encoded staphylococcal vancomycin resistance.  
The sensitivity, speed and specificity attributes suggest 
that the new vanA PCR assay is readily adaptable for use 
in a routine diagnostic microbiology laboratory. With a 
LoD of 1 CFU, the sensitivity of the new vanA PCR assay 
makes sense in that it can be relied upon to detect as low 
as one CFU of vanA in a 40 µL PCR. The ability to 
speedily detect the vanA marker with very high specificity 
by application of the novel vanA PCR assay will allow for 
timely and properly guided institution of therapy and 
infection control measures much earlier than would be 
possible by application of conventional microbiological 
culture-based assays. Thus, our work is a positive 
response to the recent suggestions that DNA-based rapid 
diagnostic testing methods could markedly enhance 
therapy and infection control (Bootsma et al., 2006).  
However, the new vanA PCR assay is not without 
limitation. It has been recently suggested that real-time 
PCR would be a more rapid diagnostic technology in the 
microbiology laboratory (Molenkamp et al., 2007). The 
cycling time of 55 min is a success. Compared with real-
time PCR assays, one major limitation of the new vanA 
PCR is the time needed to resolve the PCR amplification 
products in Agarose gel electrophoresis. Considering the 
slim budget of some laboratories, especially in the 
developing countries, it is financially impossible at the 
moment for them to acquire super diagnostic machines 
for real-time PCR, mass spectrometry and next-
generation sequencing. Therefore, this assay will find 
great application in the diagnostic microbiology of the 
developing world with tight budgets. Laboratories with 
fatter budgets can always increase on the speed of the 
new vanA PCR assay by use of appropriate fluorescent 
probe. That will exclude the gel resolution  step,  possibly 
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yielding reasonable time gains. Thus the speed limitation 
of the new vanA PCR assay is easily surmountable.  
Taken together, we are happy with the performance of 
the new vanA PCR assay. We commend the NCBI, the 
EBI and their Japanese counterparts for their huge 
success in providing publicly available genomic 
information and tools for manipulation of genomic data.  
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